Jason Kolbert
Stock Analyst at EF Hutton
(2.12)
# 1,488
Out of 4,583 analysts
68
Total ratings
46.43%
Success rate
-9.11%
Average return
Main Sectors:
Stocks Rated by Jason Kolbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMUX Immunic | Maintains: Buy | $17 | $1.95 | +771.79% | 2 | Sep 18, 2024 | |
| TRVI Trevi Therapeutics | Maintains: Buy | $21 | $3.50 | +500.00% | 2 | Sep 17, 2024 | |
| OSTX OS Therapies | Maintains: Buy | $21 | $3.55 | +491.55% | 2 | Sep 16, 2024 | |
| CLNN Clene | Maintains: Buy | $23 | $5.19 | +343.16% | 2 | Sep 16, 2024 | |
| FBLG FibroBiologics | Maintains: Buy | $16 | $3.16 | +406.33% | 2 | Sep 13, 2024 | |
| ANIX Anixa Biosciences | Maintains: Buy | $10 | $3.42 | +192.40% | 2 | Sep 9, 2024 | |
| HUMA Humacyte | Initiates: Buy | $25 | $5.45 | +358.72% | 1 | Sep 9, 2024 | |
| HOTH Hoth Therapeutics | Maintains: Buy | $5 | $0.98 | +410.20% | 2 | Sep 5, 2024 | |
| CANF Can-Fite BioPharma | Maintains: Buy | $10 | $2.02 | +395.05% | 2 | Aug 30, 2024 | |
| ENLV Enlivex Therapeutics | Initiates: Buy | $13 | $1.50 | +766.67% | 1 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 | $4.72 | +196.61% | 2 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 | $2.70 | +566.67% | 4 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 | $0.55 | +994.69% | 4 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 | $8.64 | +143.06% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.42 | +604.23% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 | $1.67 | +259.28% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $46 | $5.76 | +698.61% | 2 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $96 | $0.15 | +63,942.70% | 1 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.15 | - | 2 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7.62 → $22 | $0.15 | +14,519.49% | 1 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $120 | $0.39 | +30,669.23% | 1 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.13 | +4,515.38% | 1 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.98 | - | 2 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.40 | - | 1 | Sep 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25,200 | $0.78 | +3,230,669.23% | 1 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.19 | - | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.18 | - | 1 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.51 | - | 1 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $40 | $1.73 | +2,212.14% | 1 | Mar 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $32 | $1.13 | +2,731.86% | 8 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $720 → $480 | $3.83 | +12,432.64% | 2 | Jul 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Terminates: Sell | n/a | $6.70 | - | 4 | Jun 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $3.83 | - | 2 | Mar 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $9 | $0.24 | +3,650.00% | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $0.65 | - | 2 | May 18, 2017 |
Immunic
Sep 18, 2024
Maintains: Buy
Price Target: $17
Current: $1.95
Upside: +771.79%
Trevi Therapeutics
Sep 17, 2024
Maintains: Buy
Price Target: $21
Current: $3.50
Upside: +500.00%
OS Therapies
Sep 16, 2024
Maintains: Buy
Price Target: $21
Current: $3.55
Upside: +491.55%
Clene
Sep 16, 2024
Maintains: Buy
Price Target: $23
Current: $5.19
Upside: +343.16%
FibroBiologics
Sep 13, 2024
Maintains: Buy
Price Target: $16
Current: $3.16
Upside: +406.33%
Anixa Biosciences
Sep 9, 2024
Maintains: Buy
Price Target: $10
Current: $3.42
Upside: +192.40%
Humacyte
Sep 9, 2024
Initiates: Buy
Price Target: $25
Current: $5.45
Upside: +358.72%
Hoth Therapeutics
Sep 5, 2024
Maintains: Buy
Price Target: $5
Current: $0.98
Upside: +410.20%
Can-Fite BioPharma
Aug 30, 2024
Maintains: Buy
Price Target: $10
Current: $2.02
Upside: +395.05%
Enlivex Therapeutics
Aug 27, 2024
Initiates: Buy
Price Target: $13
Current: $1.50
Upside: +766.67%
Aug 20, 2024
Maintains: Buy
Price Target: $14
Current: $4.72
Upside: +196.61%
Aug 19, 2024
Maintains: Buy
Price Target: $18
Current: $2.70
Upside: +566.67%
Aug 19, 2024
Maintains: Buy
Price Target: $6
Current: $0.55
Upside: +994.69%
Aug 15, 2024
Maintains: Buy
Price Target: $21
Current: $8.64
Upside: +143.06%
Aug 14, 2024
Maintains: Buy
Price Target: $10
Current: $1.42
Upside: +604.23%
Aug 13, 2024
Maintains: Buy
Price Target: $6
Current: $1.67
Upside: +259.28%
Jul 29, 2024
Maintains: Buy
Price Target: $46
Current: $5.76
Upside: +698.61%
Feb 28, 2024
Initiates: Buy
Price Target: $96
Current: $0.15
Upside: +63,942.70%
Aug 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $0.15
Upside: -
Feb 6, 2023
Maintains: Buy
Price Target: $7.62 → $22
Current: $0.15
Upside: +14,519.49%
Jan 30, 2023
Initiates: Buy
Price Target: $120
Current: $0.39
Upside: +30,669.23%
Jan 6, 2023
Initiates: Buy
Price Target: $6
Current: $0.13
Upside: +4,515.38%
Nov 11, 2022
Downgrades: Neutral
Price Target: n/a
Current: $2.98
Upside: -
Sep 16, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.40
Upside: -
Aug 29, 2022
Initiates: Buy
Price Target: $25,200
Current: $0.78
Upside: +3,230,669.23%
Jul 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.19
Upside: -
May 16, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.18
Upside: -
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $2.51
Upside: -
Mar 17, 2021
Downgrades: Neutral
Price Target: $40
Current: $1.73
Upside: +2,212.14%
Nov 6, 2020
Maintains: Buy
Price Target: $33 → $32
Current: $1.13
Upside: +2,731.86%
Jul 28, 2020
Downgrades: Neutral
Price Target: $720 → $480
Current: $3.83
Upside: +12,432.64%
Jun 15, 2018
Terminates: Sell
Price Target: n/a
Current: $6.70
Upside: -
Mar 6, 2018
Downgrades: Hold
Price Target: n/a
Current: $3.83
Upside: -
Aug 17, 2017
Maintains: Buy
Price Target: $8 → $9
Current: $0.24
Upside: +3,650.00%
May 18, 2017
Upgrades: Buy
Price Target: n/a
Current: $0.65
Upside: -